Roldan V - Search Results

1

Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis.

Corral J, Hernandez-Espinosa D, Soria JM, Gonzalez-Conejero R, Ordonez A, Gonzalez-Porras JR, Perez-Ceballos E, Lecumberri R, Sanchez I, Roldan V, Mateo J, Minano A, Gonzalez M, Alberca I, Fontcuberta J, Vicente V. Corral J, et al. Among authors: roldan v. Blood. 2007 May 15;109(10):4258-63. doi: 10.1182/blood-2006-08-040774. Epub 2007 Jan 23. Blood. 2007. PMID: 17244682 Free article.

2

Effect of factor XIII VAL34LEU polymorphism on thrombolytic therapy in premature myocardial infarction.

Roldán V, Corral J, Marín F, Rivera J, Vicente V. Roldán V, et al. Thromb Haemost. 2002 Aug;88(2):354-5. Thromb Haemost. 2002. PMID: 12195711 No abstract available.

3

A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients.

González-Conejero R, Corral J, Roldán V, Martínez C, Marín F, Rivera J, Iniesta JA, Lozano ML, Marco P, Vicente V. González-Conejero R, et al. Among authors: roldan v. Blood. 2002 Sep 15;100(6):2081-6. Blood. 2002. PMID: 12200370 Free article.

4

Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction.

Roldán V, Corral J, Marín F, Rivera J, Pineda J, González-Conejero R, Sogorb F, Vicente V. Roldán V, et al. Am J Cardiol. 2003 May 15;91(10):1242-5. doi: 10.1016/s0002-9149(03)00274-1. Am J Cardiol. 2003. PMID: 12745111 No abstract available.

5

Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation.

Marín F, Corral J, Roldán V, González-Conejero R, del Rey ML, Sogorb F, Lip GY, Vicente V. Marín F, et al. Among authors: roldan v. J Mol Cell Cardiol. 2004 Sep;37(3):699-704. doi: 10.1016/j.yjmcc.2004.06.001. J Mol Cell Cardiol. 2004. PMID: 15350843

6

Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction.

Roldán V, González-Conejero R, Marín F, Pineda J, Vicente V, Corral J. Roldán V, et al. Am Heart J. 2004 Oct;148(4):602-5. doi: 10.1016/j.ahj.2004.04.020. Am Heart J. 2004. PMID: 15459589

7

Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol.

Roldán V, Corral J, Marín F, Vicente V, González-Conejero R. Roldán V, et al. J Thromb Haemost. 2004 Dec;2(12):2264-5. doi: 10.1111/j.1538-7836.2004.01027.x. J Thromb Haemost. 2004. PMID: 15613046 Free article. No abstract available.

8

A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.

Marín F, González-Conejero R, Lee KW, Corral J, Roldán V, López F, Sogorb F, Caturla J, Lip GY, Vicente V. Marín F, et al. Among authors: roldan v. J Am Coll Cardiol. 2005 Jan 4;45(1):25-9. doi: 10.1016/j.jacc.2004.09.051. J Am Coll Cardiol. 2005. PMID: 15629368 Free article.

9

Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction.

Roldán V, González-Conejero R, Marín F, Pineda J, Vicente V, Corral J. Roldán V, et al. Haematologica. 2005 Mar;90(3):421-3. Haematologica. 2005. PMID: 15749685

10

Pharmacogenetics in cardiovascular antithrombotic therapy.

Marín F, Roldán V, González-Conejero R, Corral J. Marín F, et al. Among authors: roldan v. Curr Med Chem Cardiovasc Hematol Agents. 2005 Oct;3(4):357-64. doi: 10.2174/156801605774322346. Curr Med Chem Cardiovasc Hematol Agents. 2005. PMID: 16250866 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters